Clinical trial
Combination Chemotherapy, Interferon Alfa, and Interleukin-2 in Treating…
NCT00002669 · European Organisation for Research and Treatment of Cancer - EORTC, Other · Completed
Key facts
| NCT number | NCT00002669 |
|---|---|
| Title | Combination Chemotherapy, Interferon Alfa, and Interleukin-2 in Treating Patients With Metastatic Melanoma |
| Official title | TREATMENT OF METASTATIC MELANOMA WITH DTIC, CDDP AND IFN ALPHA WITH OR WITHOUT IL-2: A RANDOMIZED PHASE III TRIAL |
| Lead sponsor | European Organisation for Research and Treatment of Cancer - EORTC, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma (Skin) |
| Intervention type | Biological, Drug |
| Interventions | aldesleukin, recombinant interferon alfa, cisplatin, dacarbazine |
| Enrollment | 90 |
| Start date | Jun 1, 1995 |
| Primary completion | Aug 1, 2002 |
| First posted | Apr 11, 2003 |
| Last update posted | Jul 2, 2012 |
| Countries | Austria, Belgium, France, Germany, Italy, Netherlands, Portugal, Switzerland, United Kingdom |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: